Therefore, understanding the degree of contribution of having APOE-ε4 allele[s] to the observed reporting of AEs, including cerebrovascular symptoms during clinical trials, might be informative for clinicians and investigators of clinical trials for AD, in a viewpoint to help distinguish some potentially confusing AEs from the symptoms due to ARIA. Here, APOE is linked to Alzheimer disease.